Showing results (251-260 of 304) with videos related to

Sort By:
Pageof 31
The Review of Scientific Instruments|July 10, 2021
Calibration of a versatile multi-energy soft x-ray diagnostic for WEST long pulse plasmasO Chellai, L F Delgado-Aparicio, P VanMeter, et al.
Cancer|January 15, 1990
Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter studyF Pandolfi, T P Loughran, G Starkebaum, et al.
Genomics|June 1, 1997
Identification of two novel isoforms of the ZNF162 gene: a growing family of signal transduction and activator of RNA proteinsC Caslini, O Spinelli, G Cazzaniga, et al.
British Journal of Haematology|November 25, 1998
Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cellsM Introna, A M Barbui, J Golay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemiaA Z Rohatiner, R Bassan, R Raimondi, et al.
British Journal of Haematology|April 7, 1999
Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemiaR Bassan, T Lerede, E Di Bona, et al.
Lancet (London, England)|June 30, 1990
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactorM Galli, P Comfurius, C Maassen, et al.
British Journal of Haematology|February 13, 2001
Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use studyR Chopra, J D Eaton, A Grassi, et al.
Leukemia|July 13, 2007
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burdenA M Vannucchi, E Antonioli, P Guglielmelli, et al.
Haematologica|December 10, 1999
Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical studyR Bassan, E Pogliani, T Lerede, et al.
Pageof 31